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Background-—Programs targeting the standard modiﬁable cardiovascular risk factors (SMuRFs: hypertension, diabetes mellitus,
hypercholesterolemia, smoking) are critical to tackling coronary heart disease at a community level. However, myocardial infarction
in SMuRF-less individuals is not uncommon. This study uses 2 sequential large, multicenter registries to examine the proportion
and outcomes of SMuRF-less ST-segment–elevation myocardial infarction (STEMI) patients.
Methods and Results-—We identiﬁed 3081 STEMI patients without a prior history of cardiovascular disease in the Australian
GRACE (Global Registry of Acute Coronary Events) and CONCORDANCE (Cooperative National Registry of Acute Coronary
Syndrome Care) registries, encompassing 42 hospitals, between 1999 and 2017. We examined the proportion that were SMuRF-
less as well as outcomes. The primary outcome was in-hospital mortality, and the secondary outcome was major adverse
cardiovascular events (death, myocardial infarction, or heart failure, during the index admission). Multivariate regression models
were used to identify predictors of major adverse cardiovascular events. Of STEMI patients without a prior history of cardiovascular
disease 19% also had no history of SMuRFs. This proportion increased from 14% to 23% during the study period (P=0.0067).
SMuRF-less individuals had a higher in-hospital mortality rate than individuals with 1 or more SMuRFs. There were no clinically
signiﬁcant differences in major adverse cardiovascular events at 6 months between the 2 groups.
Conclusions-—A substantial and increasing proportion of STEMI presentations occur independently of SMuRFs. Discovery of new
markers and mechanisms of disease beyond standard risk factors may facilitate novel preventative strategies. Studies to assess
longer-term outcomes of SMuRF-less STEMI patients are warranted. ( J Am Heart Assoc. 2019;8:e013296. DOI: 10.1161/JAHA.
119.013296.)
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T he standard modiﬁable cardiovascular risk factors(SMuRFs) of diabetes mellitus, hyperlipidemia, hyperten-
sion, and cigarette smoking are central elements of the well-
established Framingham cardiovascular risk score and many
subsequent validated risk scores.1-4 Primary and secondary
prevention programs that utilize and target susceptible individ-
uals’ modiﬁable risk factors for coronary heart disease (CHD)
have resulted in a substantial reduction in morbidity and
mortality due to CHD, particularly in high-income and some
middle-income countries.5 However, CHD remains a leading
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cause of death in all regions of the world.6-8 ST-segment–
elevation myocardial infarction (STEMI) has a higher in-hospital
mortality rate than non–ST-segment–elevation acute coronary
syndromes.9,10 In a recent large, single-center cohort study, we
reported that 25% of ﬁrst-presentation STEMI patients, con-
ﬁrmed to be a result of atherosclerosis, had no known SMuRFs
at the time of their event. Furthermore, the proportion of the
STEMI cohort that was SMuRF-less increased signiﬁcantly
during the study period (2006-2014).11
To date, in the ﬁelds of clinical and biomedical
research, there has been a lack of attention paid to the
SMuRF-less subgroup of STEMI patients. An example of this
lack of attention is the traditional means of reporting risk factor
proﬁles in STEMI clinical trials. Frequently the proportion of
patients with diabetes mellitus, hypertension, smoking, and
hypercholesterolemia are reported, but it is often difﬁcult to
extract information regarding the proportion without any
traditional risk factors. For those that do report this, the
proportion of SMuRF-lessness is similar to what we observed.12
Given the absolute number of individuals that this proportion
represents, and the mortality and morbidity of myocardial
infarction, it is critical to determine any changing patterns on a
broader scale than our single center and to formally study
patterns of management and speciﬁc outcomes of SMuRF-less
STEMI patients.
The Australian GRACE (Global Registry of Acute Coronary
Events) and CONCORDANCE (Cooperative National Registry
of Acute Coronary Syndrome Care) registries capture a large,
unbiased population of patients presenting with acute coro-
nary syndrome (ACS) to 42 hospitals across Australia, from
1999 to 2017 and provide us with an opportunity to examine
our 3 key questions: (1) What is the proportion of STEMI
patients who are SMuRF-less? (2) Is this changing over time?
(3) What are the short- and longer-term cardiovascular
outcomes of SMuRF-less STEMI patients versus those with
traditional risk factors, in a broad, representative, contempo-
rary Australian context?
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Populations
Full details of the GRACE and CONCORDANCE registry
methods have been published previously.13,14 GRACE and
CONCORDANCE employed closely aligned inclusion and
exclusion criteria designed to reﬂect an unbiased population
of patients with ACS.13,14 In addition to symptoms consistent
with myocardial ischemia, patients were required to have
either ECG changes consistent with ACS, elevation of serum
cardiac biomarkers of myocardial necrosis or documented
coronary artery disease including STEMI, non–ST-segment–
elevation myocardial infarction, and unstable angina. To enroll
an unselected population, the ﬁrst 10-20 consecutive eligible
patients were recruited from each site per month. Hospitals in
both registries were selected to represent regional and
metropolitan acute-care facilities with and without catheter-
ization laboratory facilities.
Inclusion Criteria
Patients included in this analysis were at least 18 years of age,
presented with symptoms suggestive of coronary ischemia,
and had a ﬁnal diagnosis of STEMI. For this analysis, we limited
our study to the Australian population enrolled in the GRACE
registry between 1999 and 2007 and the CONCORDANCE
registry between 2009 and 2017. No equivalent ACS registry
data were available from the participating hospitals in 2008.
An opt-out informed consent process was applied with a
waiver of consent for patients who were too ill to provide
informed consent. All participating hospitals received human
research ethics approval to participate in the registries.
Approval for this analysis was granted by the lead ethics
committee, Concord Hospital, Sydney Local Health District.
Exclusion Criteria
ACSs precipitated by a signiﬁcant noncardiovascular comor-
bidity such as anemia or trauma were excluded.13 For the
purposes of this study, only patients presenting with their ﬁrst
cardiovascular event were included in the analysis. Therefore,
patients with a known history of CHD (percutaneous
Clinical Perspective
What Is New?
• The proportion of ST-segment–elevation myocardial infarc-
tion patients without standard modiﬁable cardiovascular
risk factors is not insubstantial and has been increasing in
recent years.
• ST-segment–elevation myocardial infarction patients with-
out standard modiﬁable cardiovascular risk factors have a
higher in-hospital mortality rate than ST-segment–elevation
myocardial infarction patients with 1 or more standard
modiﬁable cardiovascular risk factors.
What Are the Clinical Implications?
• Discovery of new markers and mechanisms of coronary
artery disease beyond standard risk factors may facilitate
new preventative strategies.
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cardiovascular intervention, coronary artery bypass graft,
ACS, or history of angina pectoris), cerebrovascular disease,
or peripheral vascular disease or a ﬁnal diagnosis other than
STEMI, were excluded.
Data Sources
Data were collected by trained coordinators using standardized
case report forms. Demographic characteristics, medical history,
presenting symptoms, biochemical and electrocardiographic
ﬁndings, treatment practices, and a variety of hospital outcome
data were collected from the medical record. If a patient was
transferred to an additional facility, datawere collected fromeach
facility. Patients were recontacted at 6, 12, and 24 months
postdischarge for collection of data on unscheduled readmis-
sions, unscheduled procedures (coronary angiography, percuta-
neous coronary intervention, coronary artery bypass graft
surgery), and complications. To ensure data quality, a random
sample of submitted case report forms were audited. In this
analysis we report outcomes at 6 months only because of lower
follow-up rates at later timepoints. Standardized deﬁnitions for all
patient-related variables and clinical diagnoses were used across
the 2 registries. We refer to a known history of hypertension,
hyperlipidemia, diabetes mellitus, and current smoking as the 4
SMuRFs for cardiovascular disease (CVD). A patient was consid-
ered to be a current smoker if he or she had regularly smoked
within the past 12 months. A patient was considered to have a
known history of hyperlipidemia, diabetes mellitus, or hyperten-
sion if he or she identiﬁed as having a history of the same or was
on pharmacological treatment for these conditions at the time of
presentation. For the purposes of the study, primary analysis was
focused on patients with a ﬁnal diagnosis of STEMI presenting for
the ﬁrst time with CVD. A secondary analysis examined the
proportion of SMuRF-less patients in the registry over the same
studyperiodas theprimary analysiswithaﬁnal diagnosis non–ST-
segment–elevation acute coronary syndrome in the absence of a
prior history of CVD as deﬁned above.
Outcomes
The primaryoutcomewas in-hospitalmortality, and thesecondary
outcome was major adverse cardiovascular events (MACE)
deﬁned as death, myocardial infarction, or heart failure during
the index admission and at 6 months. The study index date for
both in-hospital and 6-month outcomes was the admission date.
The 6-month MACE was based on postdischarge events only
because not all subjects were able to be followed to 6 months.
Statistical Analyses
Categorical variables are summarized using frequencies and
percentages, whereas numerical variables are summarized
using mean, SD, median, and quartiles. Multivariable logistic
regression analyses were performed to estimate the adjusted
odds ratio and 95% CI for the binary outcomes in-hospital
mortality, in-hospital MACE, and 6-month MACE. The predic-
tor variables were the components of the GRACE risk score
(age, heart rate, systolic blood pressure, creatinine, Killip
class, cardiac arrest, ST deviation, and initial positive
biomarkers). These analyses were done within the framework
of a generalized estimating equation. The Cochrane-Armitage
trend test was used to determine if there was a trend across
the study period for the proportion of ACS subjects who were
SMuRF-less. All statistical tests were 2-tailed with the
signiﬁcance level set at 0.05. All statistical analyses are
conducted using SAS version 9.3 (SAS Institute, Cary, NC).
Results
Baseline Characteristics
Of the 13 911 patients enrolled in the GRACE Australia and
CONCORDANCE ACS registry between 1999 and 2017, 3081
patients presented with their ﬁrst cardiovascular event, had a
ﬁnal diagnosis of STEMI, and were included in the current
analysis. The median age was 61 years (interquartile range 52
to 69 years), and 2310 (75%) were male. Of the total 3081
patients, 591 (19%) had 0 SMuRFs. The most common SMuRF
was hypertension (44%), followed by current smoking (40%),
dyslipidemia (37%), and diabetes mellitus (18%) (Table 1). The
proportion of SMuRF-less STEMI patients was substantially
higher in men than women (20% versus 15%; Table 1). In
STEMI patients with and without SMuRFs there were small
differences in the mean age (60.4 years [SD 12.9] versus
61.7 years [SD 12.4]), the proportion female (26% versus
19%), mean body mass index (28.5 [SD 5.43] versus 27.0 [SD
4.37]), history of atrial ﬁbrillation (3% versus 1%), and the
proportion of patients with a family history of CHD (36%
versus 33%).
Presenting Characteristics and In-Hospital
Management
In patients with and without SMuRFs, there were no
signiﬁcant differences in hemodynamic observations, Killip
Class, cardiac arrest on admission, and GRACE risk score.
There was also no signiﬁcant difference in the incidence of
signiﬁcant multivessel disease (Table 2). A higher proportion
of SMuRF-less patients received primary percutaneous coro-
nary intervention than patients with 1 or more SMuRF (49%
versus 45%), and a smaller proportion received thrombolysis
(32% versus 37%). The proportion of SMuRF-less patients who
were transferred to another hospital was lower than those
with 1 or more SMuRFs (37% versus 44%). There was no
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clinically signiﬁcant difference in evidence-based secondary
prevention medications prescribed at time of discharge
between those with and without SMuRFs (Table 3). We
observed higher in-hospital and discharge use of angiotensin
receptor blocker therapy use in patients with 1 or more
SMuRFs. In secondary prevention angiotensin receptor
blockers are second-line therapy generally reserved for
patients unable to tolerate angiotensin-converting enzyme
inhibitors. The higher rate of use of angiotensin receptor
blockers in those with 1 or more SMuRFs may reﬂect a known
intolerance to angiotensin-converting enzyme inhibitor admin-
istration.
Changing Proportion of SMuRF-Less STEMI
During the study period from 1999 to 2017, the proportion of
STEMI patients with 0 SMuRFs increased from 14% to 23%
(Cochrane-Armitage trend test, P=0.0067; Figure 1). Although
this current study is focused on the STEMI cohort, we also
performed a simple analysis of the SMuRF-less proportion in
the 3773-subject subgroup of non–ST-segment–elevation
acute coronary syndrome GRACE/CONCORDANCE subjects
without prior CVD. It is important to note that this group is not
broadly representative of all non–ST-segment–elevation acute
coronary syndromes, as it was intentionally enriched for
patients with high-risk features based on their clinical
presentation. Although the overall proportion (18%) was
similar to that in the STEMI cohort, there was no statistically
signiﬁcant change in the SMuRF-less proportion during the
study period.
In-Hospital Outcomes
The unadjusted in-hospital mortality rate for SMuRF-less
STEMI patients was higher than that in patients with 1 or
more SMuRFs (6% versus 4%). However, the rates of recurrent
ischemic symptoms (12% versus 16%) and clinical heart failure
(7% verse 11%) were lower in SMuRF-less patients compared
with patients with 1 or more SMuRFs. There were no
differences in the rates of recurrent in-hospital myocardial
infarction, cardiogenic shock, or major bleeding between the
groups (Table 4). In a multivariable analysis SMuRF-less
status, cardiac arrest on admission, age greater than
70 years, heart rate greater than 90 beats/min, systolic
blood pressure less than 155 mm Hg, and creatinine greater
than 100 mmol/L predicted in-hospital mortality (Figure 2A).
Table 1. Baseline (Preadmission) Characteristics
Variable Statistic (Level) 0 SMuRFs (N=591) >0 SMuRFs (N=2490) Overall (N=3081)
Age Mean (SD) 61.7 (12.39) 60.4 (12.88) 60.6 (12.80)
Median (IQR) 62 (53-70) 60 (51-69) 60 (52-69)
Sex Female (%) 115 (19) 656 (26) 771 (25)
Male (%) 476 (81) 1834 (74) 2310 (75)
SMuRFs, n (%)
Diabetes mellitus 0 (0) 554 (22) 554 (18)
Hypertension 0 (0) 1363 (55) 1363 (44)
Dyslipidemia 0 (0) 1126 (45) 1126 (37)
Current smoking 0 (0) 1243 (50) 1243 (40)
BMI Mean (SD) 27.0 (4.37) 28.5 (5.43) 28.2 (5.28)
Median (IQR) 26.8 (24.2-30.0) 27.8 (24.8-31.4) 27.8 (24.8-31.6)
Family history CHD, n (%) 180 (33) 790 (36) 970 (35)
Previous atrial fibrillation, n (%) 6 (1) 86 (3) 92 (3)
Prehospitalization medications, n (%)
Statin 0 (0) 489 (20) 489 (16)
Aspirin 33 (6) 339 (14) 372 (12)
P2Y12 inhibitor 7 (1) 45 (2) 52 (2)
b-blocker 0 (0) 219 (9) 219 (7)
ACE inhibitor 0 (0) 344 (14) 344 (11)
ARB| 0 (0) 429 (17) 429 (14)
ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor antagonist blocker; BMI, body mass index; CHD, coronary heart disease; IQR, interquartile range; SMuRFs,
standard modiﬁable cardiovascular risk factors.
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In a separate multivariable analysis, age greater than
70 years, heart rate greater than 90 beats/min, systolic
blood pressure less than 155 mm Hg, cardiac arrest on
admission, Killip class greater than 1, and negative cardiac
biomarkers, but not SMuRF-less status, were all predictors of
MACE, deﬁned as death, myocardial infarction, or heart failure
during the index admission (Figure 2B).
Posthospital Outcomes
Six-month follow-up data were available for 2487 of the
original 3081 cohort (Table 5). There were no clinically
signiﬁcant differences in the unadjusted rates of recurrent
myocardial infarction, heart failure, or MACE in the ﬁrst
6 months postdischarge. In a multivariable analysis, older
age, higher heart rate, and higher Killip class but not SMuRF
status were predictors of MACE at 6 months (Table 6).
Discussion
This large, multicenter study highlights the importance of the
often-overlooked subgroup of STEMI patients with atheroscle-
rosis not predicted by SMuRFs. We validate our previous
published ﬁndings, from a single-center study, that the
proportion of SMuRF-less STEMI patients is not insubstantial
and has been signiﬁcantly increasing in recent years. The
Table 2. Patient Characteristics on Presentation
Variable Statistic (Level) 0 SMuRFs (N=591) >0 SMuRFs (N=2490) Overall (N=3081)
Systolic blood pressure at
time of presentation, mm Hg
Mean (SD) 137.6 (27.39) 137.6 (27.76) 137.6 (27.68)
Median (IQR) 136 (119-154) 135 (119-155) 136 (119-155)
Diastolic blood pressure at
time of presentation, mm Hg
Mean (SD) 82.8 (17.33) 82.1 (17.44) 82.2 (17.42)
Median (IQR) 81 (70-93) 80 (70-93) 80 (70-93)
Heart rate, beats/min Mean (SD) 77.4 (21.26) 78.9 (19.54) 78.6 (19.89)
Median (IQR) 73 (63-88) 77 (65-90) 76 (65-90)
Killip class, n (%)
1 542 (92) 2234 (90) 2776 (91)
2 31 (5) 174 (7) 205 (7)
3 9 (2) 45 (2) 54 (2)
4 6 (1) 21 (1) 27 (1)
Cardiac arrest on admission, n (%) 44 (7) 184 (7) 228 (7)
Serum creatinine, lmol/L Mean (SD) 89.7 (24.77) 91.0 (40.80) 90.7 (38.24)
Median (IQR) 87 (74-100) 84 (72-100) 85 (72-100)
Grace risk score Mean (SD) 110.5 (29.67) 108.8 (30.02) 109.15 (29.59)
Median (IQR) 108.2 (90.04-127.4) 106.0 (87.90-126.53) 106.5 (88.58-126.81)
Culprit lesion territory, n (%)
Left main 0 (0) 5 (1) 5 (1)
Left anterior descending 34 (46) 144 (37) 178 (38)
Circumflex artery 8 (11) 47 (12) 55 (12)
Right coronary 22 (30) 151 (39) 173 (37)
Unknown 10 (14) 42 (11) 52 (11)
Multivessel disease, >50% stenosis 216 (38) 1025 (42) 1241 (41)
Left ventricular function Normal, n (%) 117 (36) 509 (36) 626 (36)
Mild impairment, n (%) 116 (36) 493 (34) 609 (35)
Moderate impairment, n (%) 65 (20) 353 (25) 418 (24)
Severe impairment, n (%) 25 (8) 76 (5) 101 (6)
IQR indicates interquartile range; SMuRFs, standard modiﬁable cardiovascular risk factors.
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relevance of this underappreciated group of STEMI patients is
further highlighted by the observed higher in-hospital mortal-
ity in this group.
The substantial proportion with no SMuRFs at the time of
their index event is consistent with previously published
studies at 18% overall12,15-17 and represents a signiﬁcant
burden of CVD at a national and global scale, with an
estimated 7.3 million acute myocardial infarctions per year
worldwide.5. The STEMIs in the SMuRF-less group were not
explained by obesity, family history of premature coronary
artery disease, or age (with body mass index being less in the
SMuRF-less group than the explained STEMI group, similar
rates of relevant family history, and similar ages). It is
interesting to observe that the proportion of SMuRF-less
STEMI patients was a third higher in men than women.
The YOUNG-MI registry similarly found that 17% of ACS
patients aged less than 50 years old presenting with a type 1
acutemyocardial infarction had noSMuRFs and in addition found
that fewer than50%ofpatients in their cohortwouldhavemet the
criteria for primary prevention statin therapy according to current
American guidelines.17 Although it is essential that we continue
at a community and primary healthcare level to identify and
address the burden of known risk factors for atherosclerosis,
parallel efforts should continue toward unraveling the biological
mechanisms underlying disease in SMuRF-less individuals. New
technologies and data science advances in omics andmultiomics
approaches will allow novel discovery approaches to be adopted
in accurately phenotyped cohorts with the potential to identify as
yet unknownbiological networks and processes.18 Polygenic risk
scores have been developed that can stratify an individual’s risk
largely independent of the individual’s SMuRFs and can improve
risk prediction over traditional risk factor–derived scores.19
Future cohort studies such as GRACE and CONCORDANCE
registries would beneﬁt from building biobanks into their study
design to enable validation of these scores as well as identiﬁ-
cation of new biomarkers.
The ultimate marker of risk for myocardial infarction is a
noninvasive measure of early atherosclerotic disease itself,
integrating not just the “attacking” risk factors but also the
host “response.”18 Currently, in clinical practice, cardiac
computed tomography—both coronary calcium score and
coronary angiography—are all that we have available.
Research tools measuring early vascular dysfunction or
disease include carotid intimal medial thickness and brachial
artery reactivity.20,21 But there is an absence of circulating
blood markers of atherosclerosis “activity,” with the non-
speciﬁc inﬂammatory marker high-sensitive C-reactive protein
being the closest clinically available measure that we have.
Application of noninvasive imaging of subclinical vascular
disease supports the importance of the problem. One recent
study demonstrated evidence of atherosclerosis in 50% of
adults without SMuRFs.21 Another study showed that in
asymptomatic adults with no SMuRFs, 32% had evidence of
coronary artery calciﬁcation, and 12% had moderate or severe
coronary artery calciﬁcation, deﬁned as a coronary artery
calcium score greater than 100 Agatston units.22 Currently,
international guidelines do not recommend screening with
coronary artery calcium or computed tomographic coronary
angiography in patients deemed at low risk based on
traditional risk factor scores.23-25 Data highlighting the burden
of disease in the SMuRF-less population and the dramatic
difference earlier detection and targeted prevention would
make suggest the need for more widely accessible markers of
subclinical disease particularly relevant for these individuals.
This is the ﬁrst report, in a large, multicenter study, of an
increase in the proportion of SMuRF-less STEMI patients. This
increase may be explained by a simple competing risks
principle, with improved identiﬁcation and effective manage-
ment of SMuRFs in primary care effectively increasing the
relative proportion of patients with minimal risk factors that
have received little recognition to date. Alternatively, it is
Table 3. Medical Management and Cardiac Procedures
Variable
0 SMuRFs
(N=91)
>0 SMuRFs
(N=2490)
Overall
(N=3081)
In-hospital treatment, n (%)
Statin 535 (91) 2267 (91) 2802 (91)
Aspirin 571 (97) 2437 (98) 3008 (98)
P2Y12 receptor inhibitor 502 (85) 2077 (83) 2579 (84)
ACE inhbitor 446 (76) 1728 (70) 2174 (71)
ARB 5 (1) 317 (13) 322 (10)
Heparin 461 (78) 1939 (78) 2400 (78)
Low-molecular-weight
heparin
203 (34) 793 (32) 996 (32)
Thrombolysis 188 (32) 919 (37) 1107 (36)
Primary PCI in STEMI
patients
291 (49) 1099 (44) 1390 (45)
Hospital transfer 219 (37) 1086 (44) 1305 (42)
PCI 415 (70) 1708 (69) 2123 (69)
CABG 25 (4) 150 (6) 175 (6)
Discharge medications, n (%)
Statin 495 (91) 2152 (92) 2647 (92)
Aspirin 486 (89) 2122 (91) 2608 (90)
P2Y12 inhibitor 437 (80) 1813 (78) 2250 (78)
b-blocker 453 (83) 1953 (84) 2406 (83)
ACE inhibitor 390 (71) 1588 (68) 1978 (69)
ARB 9 (2) 256 (11) 265 (9)
ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor antagonist
blocker; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention;
SMuRFs, standard modiﬁable cardiovascular risk factors; STEMI, ST-segment–elevation
myocardial infarction.
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plausible that environmental factors such as air particulate
matter and heavy metal exposure levels or other unknown
factors may have changed and may be contributing to
atherosclerotic events in individuals without SMuRFs.26-28
A major goal of these analyses was to investigate the
outcomes of SMuRF-less STEMI patients compared with their
counterparts whose myocardial infarctions were more easily
explained by traditional risk factors. We conﬁrmed previous
observations that SMuRF-less myocardial infarction patients
were more likely to die in hospital than those with 1 or more
SMuRFs.15,16,29 This does not appear to reﬂect treatment
differences (Table 3). These data need to be more widely
communicated to front-line physicians to ensure that timely
evidence-based care is provided to this vulnerable group of
patients. Despite the higher in-hospital mortality in SMuRF-
less individuals, the rates of MACE, including in-hospital
Figure 1. Increasing proportion of ST-segment–elevation myocardial infarction (STEMI) patients with 0
standard modiﬁable cardiovascular risk factors (SMuRFs) during the study period. Cochrane-Armatage
trend test P=0.0067.
Table 4. Unadjusted In-Hospital Outcomes
Variable Statistic (Level) 0 SMuRFs (N=91) >0 SMuRFs (N=2490) Overall (N=3081)
In-hospital MACE, % 88 (16%) 406 (18%) 494 (18%)
In-hospital death, % 36 (6) 107 (4) 143 (5)
Myocardial infarction, % 11 (2) 54 (2) 65 (2)
Cardiogenic shock, % 38 (6) 117 (5) 155 (5)
In-hospital death or myocardial infarction, % 44 (8) 154 (7) 198 (7)
Recurrent ischemic symptoms, % 68 (12) 386 (16) 454 (15)
Heart failure, % 43 (7) 277 (11) 320 (10)
Major bleeding, % 40 (7) 149 (6) 189 (6)
Stroke, % 2 (0) 16 (1) 18 (1)
Length of stay, d Mean, SD 6.7 (17.13) 6.4 (9.90) 6.4 (11.62)
Median, IQR 4 (3-6) 4 (3-7) 4 (3-6)
IQR indicates interquartile range; MACE, major adverse cardiovascular events (death/myocardial infarction/heart failure/shock); SMuRFs, standard modiﬁable cardiovascular risk factors.
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Figure 2. Multivariate odds ratios for in-hospital (A) death and (B) major adverse cardiac events
(MACE: death/recurrent myocardial infarction/heart failure/cardiogenic shock). Bars indicate 95% CIs.
HF indicates heart failure; MI, myocardial infarction; OR, odds ratio; SMuRFs, standard modiﬁable
cardiovascular risk factors (hypertension, diabetes mellitus, hypercholesterolemia, and smoking).
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recurrent myocardial infarctions and cardiogenic shock were
similar. The higher in-hospital mortality rate may reﬂect
differing underlying biological processes or a reduced capacity
to tolerate myocardial ischemia, and mechanisms of in-
hospital mortality in SMuRF-less individuals warrant further
investigation.30
There are a number of limitations in our study deserving of
mention. SMuRFs were documented as categorical variables,
although each SMuRF is actually a continuous variable.31
Identiﬁcation of SMuRF status is based on interrogation of
medical records and was not independently validated with
biochemical testing; thus, it may be susceptible to under-
diagnoses. Furthermore, less commonly used risk factors
such as lipoprotein(a), high-sensitivity C-reactive protein,
coronary artery calcium score, and genetic risk scores were
not available and therefore not assessed in this study.32
However, this real-world study reﬂects the information that is
readily available to clinicians. A total of 19% of subjects were
lost to follow-up at 6 months; this may have resulted in a
potential bias. However, as shown in Table S1, there were
only subtle differences in the demographic and clinical
features between the 2 groups, with a slightly higher Grace
Risk Score, creatinine, and Killip class in those lost to follow-
up compared with those who were able to be contacted for
follow-up. It was due to the loss to follow-up that the 6-month
data were considered secondary and treated as descriptive.
The speciﬁc timing of events within the 6-month follow-up
period was not captured, and we were unable to assess the
proximity of events to the index event or to learn whether
there was an association between length of stay and early
postdischarge events. Continued efforts are required to
examine progression of atherosclerosis and related outcomes
in SMuRF-less subjects.
Conclusions
In these multicenter registry studies spanning nearly
20 years, 19% of STEMI patients without a prior history of
CVD also had no prior history of SMuRFs. The proportion of
Table 5. Unadjusted Outcomes 6 Months Postdischarge
Variable
0 SMuRFs
n (%)
N=471
>0 SMuRFs
n (%)
N 016
Overall
n (%)
N=2487
MACE, % 20 (6) 101 (7) 121 (7)
Death/MI, % 16 (4) 76 (4) 92 (4)
Death, % 9 (2) 48 (2) 57 (2)
MI, % 7 (2) 34 (2) 41 (2)
Recurrent revascularization, % 14 (3) 62 (3) 76 (3)
CHF, % 6 (2) 29 (2) 35 (2)
Recurrent angina, % 24 (7) 98 (7) 122 (7)
Major bleeding, % 2 (1) 6 (0) 8 (0)
Stroke, % 0 (0) 15 (1) 15 (1)
CHF indicates congestive heart failure; MACE, major adverse cardiovascular events
(death/myocardial infarction/heart failure/shock); MI, myocardial infarction; SMuRFs,
standard modiﬁable cardiovascular risk factors.
Table 6. Multivariable Logistic Regression Model for 6-Month
MACE
Parameter Effect Odds Ratio (95% CI) P Value
SMuRFs >0 SMuRFs 1.27 (0.72, 2.26) 0.407
0 SMuRFS Ref
Killip class 2 2.8 (1.58, 4.97) 0.013
3 8.42 (2.71, 26.18)
4 2.59 (0.57, 11.8)
1 Ref
Cardiac arrest on
admission
Yes 0.35 (0.13, 0.94) 0.019
No Ref
Index ST deviation Yes 0.79 (0.27, 2.31) 0.696
No Ref
Positive cardiac
biomarkers
Yes 0.21 (0.07, 0.61) 0.095
No Ref
Prehospital aspirin Yes 1.25 (0.77, 2.05) 0.388
No Ref
Hospital transfer Yes 0.82 (0.53, 1.28) 0.371
No Ref
Age group, y <50 0.29 (0.17, 0.51) 0.010
50 to 59 0.22 (0.12, 0.42)
60 to 69 0.41 (0.23, 0.74)
70+ Ref
Heart rate group, bpm <65 0.54 (0.31, 0.94) 0.094
65 to 74 0.37 (0.17, 0.83)
75 to 89 0.68 (0.38, 1.22)
90+ Ref
Systolic blood pressure
group, mm Hg
<120 1.18 (0.68, 2.05) 0.798
120 to 134 1.12 (0.56, 2.23)
135 to 154 0.89 (0.5, 1.59)
155+ Ref
Serum creatinine at
admission, mmol/L
<70 0.59 (0.35, 1) 0.033
70 to 84 0.54 (0.37, 0.78)
85 to 99 0.42 (0.25, 0.69)
100+ Ref
MACE indicates major adverse cardiovascular events (death/myocardial infarction/heart
failure/shock); SMuRFs, standard modiﬁable cardiovascular risk factors.
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STEMI patients with no SMuRFs increased from 14% to 23%
during the study period. SMuRF-less STEMI patients had
higher in-hospital mortality rates when compared with
patients with 1 or more SMuRFs. Our study highlights the
need for ongoing investigation and for discovery of novel risk
factors, biomarkers, biological processes, and treatment
targets in order to better address the changing nature of
coronary artery disease in the 21st century.
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SUPPLEMENTAL MATERIAL 
 
Table S1. Baseline, presentation and in-hospital management characteristics of subjects with 6 month 
follow up data versus those without 6 month follow up data. 
 
Variable Statistic/Level 
6 month 
follow up 
data 
collected  
N=2487 
Lost to follow 
up 
N=594 
Overall 
 
N=3081 
Age Mean (SD) 60.3 (12.6) 62.3 (12.5) 60.6 (12.8) 
 Minimum 23.0 23.0 23.0 
 Median (IQR) 60 (51-79) 62 (52-71) 60 (52-69) 
Sex Female (%) 606 (24) 165 (28) 771 (25) 
 Male (%) 1881 (76) 429 (72) 2310 (75) 
SMuRFs*     
   Diabetes (%)  442 (18) 112 (19) 554 (18) 
   Hypertension (%)  1096 (44) 267 (45) 1363 (44) 
   Dyslipidaemia (%)  933 (38) 193 (32) 1126 (37) 
   Current smoker (%)  1008 (41) 235 (40) 1243 (40) 
Family history of coronary heart disease 
(%) 
 805 (37) 165 (29) 970 (35) 
BMI† Mean (SD) 28.3 (5.3) 28.1 (5.3) 28.2 (5.3) 
 Median (IQR) 27.4 (24.8-
30.9) 
27.5 (24.5-
30.9) 
27.4 (24.7-
30.9) 
Previous atrial fibrillation (%)  67 (3) 25 (4) 92 (3) 
Variable Statistic/Level 
6 month 
follow up 
data 
collected  
N=2487 
Lost to follow 
up 
N=594 
Overall 
 
N=3081 
History of bleeding (%)  24 (1) 3 (1) 27 (1) 
Pre-hospital medications     
   Statin (%)  398 (16) 91 (15) 489 (16) 
   Aspirin (%)  309 (12) 63 (11) 372 (12) 
   P2Y12 Inhibitor (%)  40 (2) 12 (2) 52 (2) 
   Betablocker (%)  175 (7) 44 (7) 219 (7) 
   ACE inhibitor (%)§  284 (11) 60 (10) 344 (11) 
   ARB (%)||  337 (14) 92 (16) 429 (14) 
Systolic blood pressure (mmHg) Mean (SD) 138.1 (21.2) 135.3 (29.7) 137.6 (27.7) 
 Median (IQR) 136 (120-155) 135 (115-155) 136 (119-155) 
Diastolic blood pressure (mmHg) Mean (SD) 82.5 (17.2) 81.0 (18.3) 82.2 (17.4) 
 Median (IQR) 80 (70-92) 80 (70-93) 80 (70-93) 
Heart rate (per min) Mean (SD) 78.0 (19.3) 80.9 (22.0) 78.6 (19.9) 
 Median (IQR) 76 (64-90) 78 (65-94) 76 (65-90) 
Killip class 1 2268 (92) 508 (86) 2776 (91) 
 2 159 (6) 46 (8) 205 (7) 
 3 34 (1) 20 (3) 54 (2) 
 4 12 (0) 15 (3) 27 (1) 
Variable Statistic/Level 
6 month 
follow up 
data 
collected  
N=2487 
Lost to follow 
up 
N=594 
Overall 
 
N=3081 
Cardiac arrest on admission  154 (6) 74 (13) 228 (7) 
Abnormal cardiac biomarker  2052 (98) 494 (98) 2546 (98) 
Serum creatinine Mean (SD) 89.1 (29.0) 97.5 (63.3) 90.7 (38.2) 
 Median (IQR) 84 (72-100) 88 (73-104) 85 (72-100) 
Grace Risk Score (Fox) Mean (SD) 107.5 (28.1) 116.5 (34.4) 109.2 (29.6) 
 Median (IQR) 106 (88-125) 111 (91-136) 107 (89-127) 
Left Ventricular function grade     
   Normal (%)  508 (36) 118 (36) 626 (36) 
   Mild impairment (%)  512 (36) 97 (29) 609 (35) 
   Moderate impairment (%)  329 (23) 89 (27) 418 (24) 
   Severe impairment (%)  73 (5) 28 (8) 101 (6) 
Culprit Lesion Territory     
   Left main (%)  4 (1) 1 (2) 5 (1) 
   Left Anterior Descending (%)  153 (38) 25 (39) 178 (38) 
   Circumflex Artery (%)  48 (12) 7 (11) 55 (12) 
   Right Coronary (%)  148 (37) 25 (39) 173 (37) 
   Unknown (%)  46 (12) 6 (9) 52 (11) 
Multi-vessel disease > 50% stenosis (%)  1013 (41) 228 (42) 1241 (41) 
Variable Statistic/Level 
6 month 
follow up 
data 
collected  
N=2487 
Lost to follow 
up 
N=594 
Overall 
 
N=3081 
In-hospital treatment     
  Statin (%)  2318 (93) 484 (82) 2802 (91) 
   Aspirin (%)  2452 (99) 556 (94) 3008 (98) 
   P2Y12 Inhibitor (%)  2071 (83) 508 (86) 2579 (84) 
ACE Inhbitor (%)§  1819 (73) 355 (60) 2174 (71) 
ARB (%)||  251 (10) 71 (12) 322 (10) 
Heparin (%)  1938 (78) 462 (78) 2400 (78) 
Low molecular weight heparin (%)  830 (33) 166 (28) 996 (32) 
Thrombolysis (%)  921 (37) 186 (31) 1107 (36) 
Primary PCI in STEMI patients (%)‡§  1113 (45) 277 (47) 1390 (45) 
   Hospital transfer (%)  1055 (42) 250 (42) 1305 (42) 
PCI (%)‡  1724 (69) 399 (67) 2123 (69) 
CABG (%)Ï  143 (6) 32 (5) 175 (6) 
Discharge medications     
Statin (%)  2192 (93) 455 (84) 2647 (92) 
Aspirin (%)  2144 (92) 464 (86) 2608 (90) 
P2Y12 Inhibitor (%)  1832 (78) 418 (77) 2250 (78) 
Betablocker (%)  2003 (85) 403 (74) 2406 (83) 
Variable Statistic/Level 
6 month 
follow up 
data 
collected  
N=2487 
Lost to follow 
up 
N=594 
Overall 
 
N=3081 
ACE inhibitor (%)§  1675 (71) 303 (56) 1978 (69) 
 ARB (%)||  205 (9) 60 (11) 265 (9) 
 
*Standard modifiable cardiovascular risk factors (SMuRFs) 
†Body mass index (BMI) 
‡Coronary heart disease(CHD) 
§Angiotensin converting enzyme (ACE) 
||Angiotensin II Receptor Antagonist Blocker (ARB) 
‡Percutaneous coronary intervention (PCI) 
§ST elevation myocardial infarction (STEMI) 
Ï Coronary artery bypass graft surgery (CABG) 
 
